川姐 personal page - To The Moon

川姐

No personal profile

164Follow

25Followers

0Topic

0Badge

2021-01-31

$Zomedica Pharmaceuticals Corp.(ZOM)$Waiting for March!??

2022-08-12

$T2 Biosystems(TTOO)$💪💪

2021-02-09

$Bionano Genomics(BNGO)$Yeah!! Going to chiong tonight?

2021-04-14

$HUMBL Inc.(HMBL)$Jia you!!! Please up up ?

2021-03-20

Good

Sorry, the original content has been removed

2022-09-06

$T2 Biosystems(TTOO)$Really sad

2021-06-01

Top

Sorry, the original content has been removed

2021-02-13

$Bionano Genomics(BNGO)$Nice!

2021-01-28

$Zomedica Pharmaceuticals Corp.(ZOM)$Long wait.. still waiting.. :(

2022-05-03

$Inuvo(INUV)$Long long wait!!

2022-04-19

$HUMBL Inc.(HMBL)$Sad 😞

2021-03-01

$Inuvo(INUV)$Seeing light!!

2021-02-14

Nice

Sorry, the original content has been removed

2021-06-01

Positive news

Sorry, the original content has been removed

2021-03-29

Like

Sorry, the original content has been removed

2021-02-01

$Sundial Growers Inc.(SNDL)$??

2022-03-03

$BlockQuarry Corp.(BLQC)$

2021-09-23

Keep going!

Despite Vaccine Uncertainty, Pfizer Is a Buy

2021-06-01

Good news

Sorry, the original content has been removed

2021-04-25

Cool

Sorry, the original content has been removed

Go to Tiger App to see more news

Invest in Global Markets with Tiger Brokers!

Open App

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3572316149124317","uuid":"3572316149124317","gmtCreate":1609222125786,"gmtModify":1706620738236,"name":"川姐","pinyin":"cjchuanjie","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":25,"headSize":164,"tweetSize":261,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":306004759220312,"gmtCreate":1715743442784,"gmtModify":1715743599670,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"https://www.reuters.com/business/us-makers-masks-gloves-get-lifeline-higher-tariffs-chinese-made-products-2024-05-14/","listText":"https://www.reuters.com/business/us-makers-masks-gloves-get-lifeline-higher-tariffs-chinese-made-products-2024-05-14/","text":"https://www.reuters.com/business/us-makers-masks-gloves-get-lifeline-higher-tariffs-chinese-made-products-2024-05-14/","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/306004759220312","isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931509538,"gmtCreate":1662474757224,"gmtModify":1676537068555,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931509538","repostId":"9931509291","repostType":1,"repost":{"id":9931509291,"gmtCreate":1662474744013,"gmtModify":1676537068555,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>Really sad","listText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>Really sad","text":"$T2 Biosystems(TTOO)$Really sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931509291","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931509291,"gmtCreate":1662474744013,"gmtModify":1676537068555,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>Really sad","listText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>Really sad","text":"$T2 Biosystems(TTOO)$Really sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/9931509291","isVote":1,"tweetType":1,"viewCount":1519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9933451668,"gmtCreate":1662339414854,"gmtModify":1676537039120,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AIY.SI\">$IFAST CORPORATION LTD.(AIY.SI)$</a>Up 🆙&nbsp;","listText":"<a href=\"https://ttm.financial/S/AIY.SI\">$IFAST CORPORATION LTD.(AIY.SI)$</a>Up 🆙&nbsp;","text":"$IFAST CORPORATION LTD.(AIY.SI)$Up 🆙","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9933451668","isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9997849551,"gmtCreate":1661784475375,"gmtModify":1676536578203,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9997849551","repostId":"9997823124","repostType":1,"repost":{"id":9997823124,"gmtCreate":1661781765576,"gmtModify":1676536577687,"author":{"id":"9000000000000366","authorId":"9000000000000366","name":"UrsulaFowler","avatar":"https://static.tigerbbs.com/683cd1223c3065ee08d830f973212930","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000366","authorIdStr":"9000000000000366"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BBBY\">$Bed Bath &amp; Beyond(BBBY)$</a> NASDAQ:BBBY pulled off an improbable rise on Friday despite the broader markets tumbling to close the week.Shares of BBBY rose higher by 5.94% and closed the trading week at a price of $10.70.Stocks were hammered on Friday as FedChairman Jerome Powelldelivered a hawkish speech from Jackson Hole that hinted at more pain ahead for the US economy. The eight-minute speech was short and to the point, and caused an immediate crash on Wall Street. Overall, the Dow Jones sank by 1,008 basis points, the S&amp;P 500 dropped lower by 3.37%, and the NASDAQ tumbled by 3.94% during the session.How did Bed Bath and Beyond manage to eke out a positive day despite the broad market sell off?The daily trading volume soared past the recent","listText":"<a href=\"https://laohu8.com/S/BBBY\">$Bed Bath &amp; Beyond(BBBY)$</a> NASDAQ:BBBY pulled off an improbable rise on Friday despite the broader markets tumbling to close the week.Shares of BBBY rose higher by 5.94% and closed the trading week at a price of $10.70.Stocks were hammered on Friday as FedChairman Jerome Powelldelivered a hawkish speech from Jackson Hole that hinted at more pain ahead for the US economy. The eight-minute speech was short and to the point, and caused an immediate crash on Wall Street. Overall, the Dow Jones sank by 1,008 basis points, the S&amp;P 500 dropped lower by 3.37%, and the NASDAQ tumbled by 3.94% during the session.How did Bed Bath and Beyond manage to eke out a positive day despite the broad market sell off?The daily trading volume soared past the recent","text":"$Bed Bath & Beyond(BBBY)$ NASDAQ:BBBY pulled off an improbable rise on Friday despite the broader markets tumbling to close the week.Shares of BBBY rose higher by 5.94% and closed the trading week at a price of $10.70.Stocks were hammered on Friday as FedChairman Jerome Powelldelivered a hawkish speech from Jackson Hole that hinted at more pain ahead for the US economy. The eight-minute speech was short and to the point, and caused an immediate crash on Wall Street. Overall, the Dow Jones sank by 1,008 basis points, the S&P 500 dropped lower by 3.37%, and the NASDAQ tumbled by 3.94% during the session.How did Bed Bath and Beyond manage to eke out a positive day despite the broad market sell off?The daily trading volume soared past the recent","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9997823124","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":799,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9997887055,"gmtCreate":1661780561086,"gmtModify":1676536577329,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a> 😢&nbsp;","listText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a> 😢&nbsp;","text":"$T2 Biosystems(TTOO)$ 😢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9997887055","isVote":1,"tweetType":1,"viewCount":1310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9990129830,"gmtCreate":1660312167922,"gmtModify":1676533449072,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9990129830","repostId":"1190571853","repostType":4,"repost":{"id":"1190571853","kind":"news","pubTimestamp":1660308827,"share":"https://ttm.financial/m/news/1190571853?lang=&edition=full_marsco","pubTime":"2022-08-12 20:53","market":"us","language":"en","title":"Palantir: Utter Disaster","url":"https://stock-news.laohu8.com/highlight/detail?id=1190571853","media":"Seeking Alpha","summary":"SummaryThere is no faith in Palantir right now.Headline results were mixed at best.Expenses are on t","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>There is no faith in Palantir right now.</li><li>Headline results were mixed at best.</li><li>Expenses are on the rise, but cash flow is positive and the balance sheet is pristine.</li><li>The pace of growth is clearly slowing, and that is a major issue for an earnings-light company.</li></ul><p>So, Palantir Technologies Inc. (NYSE:PLTR) stock has been one of the best trading stocks you can ask for. It moves with extreme swings higher and lower, our traders have made a bundle, especially by selling premium (i.e., puts and calls). We have stood behind the technology as a gamechanger. This is truly an innovative and disruptive company that has massive reach to both the commercial and government sectors.</p><p>The company is operating in the most important currency of our lifetimes: big data. And while the company innovates, and helps its clients understand data and make decisions, as an investment this has been complete trash, really an utter disaster. That may not be a technical finance term in the literature, but it is a term you hear often at hedge funds and trading floors. Frankly, while we believe in the ability of the company to deliver long-term, and we own some of it, it has been an utter disaster for longs that are not trading in and out. While we are up off the bottom, there are still so many retail &#34;bag-holders&#34; out there.</p><p><b>Trading not investing</b></p><p>The only ones making money in this stock are trading in and out. You can make good money holding a core investment and selling calls, or even selling puts, due to the volatility. Those who scalp nickels and dimes are doing well. Those who are caught near the bottom are hit hard. But investing here requires extreme patience, and frankly, while we get the win on the trades over and over, we recognize that investors are getting slammed here.</p><p><b>Pressure mounts</b></p><p>Unfortunately, despite a market rally, this remains a trader&#39;s market right now, and we think that is the best way to handle Palantir for now. That said, we think you can hold a small core position for the long-term, but with all of the issues facing the company from dilution to a questionable management team, the economic picture has been poor for the company, making matters worse. Governments are spending less. Businesses are tightening up. While we think you can see business recognize the money saving potential of decision making algorithms, company capex on things like this tends to get cut first when businesses tighten their belt. This is a near-term issue, while things like dilution are longer-term. The thing is, we think you should trade this name. We hate to see investors lose money, and we know it can be painful, but it&#39;s been complete trash, in our humble opinion. Is all hope lost here?</p><p><b>Companies like Palantir tend to be expensive before they finally sustain earnings</b></p><p>Companies like Palantir are indeed often extremely expensive in the early stages. Granted, this company has been around for a long time, but is newly public, barely two years old here public. You really cannot value them on an earnings basis because there are no or very little earnings often as they ramp up. Palantir, as we mentioned has that massive dilution problem, which means consistent positive EPS gets kicked further down the road. We think Palantir has a lot of potential, but this market is beyond unforgiving to those companies that do not make money or have sky high valuations. The last few weeks have seen a huge tech rally, and Palantir stock began to see a big bid up, until this week.</p><p><b>Little faith in Palantir</b></p><p>Investors are now starting to see that Palantir may lose money or breakeven for years. Of course, the theory goes that companies like this will lose money as they spend to attract customers and build their moat. They invest heavily in their growth while seeing revenues increase dramatically. And as we know, Palantir is seeing revenues grow tremendously, but even that pace of growth is slowing, and that is a huge risk. If you believe in the tech (we do) you can add selectively to a well-rounded portfolio to improve cost basis, and put faith in management that it can deliver on growing the business profitably without diluting shareholders into oblivion, but it may take years to get a return. It is just easier to make 5,6,7, even 10% on this name by trading over and over. Investing requires patience and belief that things will improve. Right now, this is a tall order for this company and management. There is no, or very little faith.</p><p>While operationally the company is growing sufficiently, management has some credibility issues. What one has to do is determine if what the company offers will solve enough headaches for customers that eventually the growing sales turn into sustained and growing profits. However, the most recent quarter was also &#34;trash,&#34; as we say.</p><p><b>Headline earnings figures mixed</b></p><p>In the just-reported quarter, performance was pretty mixed on the top and bottom lines with revenue just a touch ahead of consensus estimates, and earnings missing horribly. Total revenue grew 25.9% year-over-year to $473.0 million, beating estimates by just over $1 million. However, its profitability was lower than expected by $0.04, and worse, guidance was far less than consensus. That crushed the stock&#39;s momentum that it had going for it. Now revenues are only growing in the 20% range, versus 30+. Ouch. Further, most expected the company to make a tiny profit this quarter, and instead it lost money. Ouch.</p><p><b>Palantir&#39;s Government and Commercial sectors both showing growth</b></p><p>As you likely are aware, Palantir has two reporting segments: both the government and commercial segments. The commercial revenue stream continues to grow rapidly, while government results seem to be slowing. There is a ton of disagreement out there on whether the somewhat shaky economy will help or hurt, but we think it definitely slows both sectors, especially government.</p><p>Deceleration of revenue growth is definitely a negative for a company like this that does not enjoy high earnings. The revenues did rise 26% from last year, and the company&#39;s customer count increased to 304, up from 169 a year ago, but sequentially customer growth seems to be slowing. Palantir added 27 net new customers in the second quarter, with 19 net new commercial customers. We think it is important to note that the commercial space is doing well. The commercial revenue is expanding rapidly, increasing 132% in 2021, and here in Q2, it rose 46% year-over-year. That said, each earnings report it seems the year-over-year growth is a little less. Not great.</p><p>The government business growth has just stalled. Here government revenue expanded to $263 million in revenue in Q2, rising 9% quarter-over-quarter. One positive is that health care (both in government and also commercial) has become a substantial and rapidly growing business, generating approximately $153 million in revenue in the first half of 2022, up from $42 million in the first half of 2020. Decent growth.</p><p><b>Margins show good news</b></p><p>For as much as the company seemed to have whiffed, there has been pockets of good news. Palantir is seeing very positive momentum in its margins. Positive movement in margins is important in a software company as it really highlights strengths, or weaknesses, in the way it distributes its products. Palantir is delivering here. Adjusted gross margin, (these are the margins which excludes the horrible dilutive stock-based compensation expenses) was 81%. The adjusted income from operations, excluding stock-based compensation and related employer payroll taxes, was $108 million, representing adjusted operating margin of 23% ahead of management&#39;s prior guidance of 20%.</p><p>Palantir expenses are on the rise but cash flow is positive.</p><p>While margins were solid, adjusted expenses are on the rise. Expenses were $365 million, up 11% sequentially. With the revenue number and higher expenses however, despite margins, led to a loss in the quarter. As mentioned adjusted earnings per share was a loss of $0.01. Some of this was that there was a $0.05 impact driven primarily by losses on securities held.</p><p>The company also generated $62 million in cash from operations, and the adjusted free cash flow was $61 million. That was the seventh consecutive quarter of positive free cash flow. Over the last year Palantir generated $314 million in adjusted free cash flow. The balance sheet is anything but trash. The company still has a solid $2.4 billion in cash and cash equivalents and absolutely no debt. Now that said, the company did decide a few weeks ago to expand its revolving credit facility by adding a $450 million new incremental delayed draw term loan facility. Long story short, the company has liquidity if needed. Overall, they have an additional liquidity source up to $950 million and it remains entirely undrawn.</p><p>The reason we explain that is this company is in no danger of any sort of bankruptcies. The investment might be horrible as sustained positive EPS remains elusive, but the balance sheet is nice.</p><p><b>Palantir stock valuation</b></p><p>When we look at the valuation of Palantir stock, the bottom line is the stock is expensive to own. Sure, looking at traditional price-to-earnings is futile, but if you did you would see a stock at like 170X FWD EPS. Very pricey. Perhaps the more appropriate measure is the price-to-sales ratio, but not only is this still very high, the market has basically said it is no longer willing to pay for sky high multiples here in 2022. Keep that in mind. At 10.4X sales, the stock is relatively cheaper than it has ever been, but it is still not &#34;cheap&#34; by any stretch at all. We like the cash flow metrics, though the price to cash flow is still about 70X.</p><p><b>Guidance was more than disappointing</b></p><p>The biggest concern right now is not valuation, or the Q2 earnings results. Nor is it the fact that the stock has been a trash investment. The biggest issue right now is also not the never ending dilution (which stinks). It is not the broader market risk either. The largest issue is a slowdown in performance, the slowing growth of revenues, and continued reduced guidance including here in Q3. The Q3 guidance was pretty weak. For Q3 2022, the company &#34;expects revenue of between $474 million to $475 million&#34; which was way below consensus of $505 million. For the year, we are looking at nearly 5% lower revenues than expected. Ouch. For the year management guided &#34;revenue of $1.9 billion&#34; vs. consensus of $1.98 billion. Adjusted income from operations should be $341 million to $343 million.</p><p>So, what is our take?</p><p>We would be selling calls here on the next pop. The volatility is high here and premiums are hefty. On the next big downturn, sell puts a month or two out and out of the money. If assigned, turn right around and sell calls. Trade around the position. Palantir&#39;s growth is slowly fading, though still strong. We also think profitability is elusive. Dilution could continue so long that positive EPS becomes out of reach without future buybacks. Stick to trading the name, or buy a few shares and come back in 10 years.</p><p><b>Take home</b></p><p>We love that the company operates with no debt and has nice positive free cash flow. The company offers amazing solutions for government and businesses by using big data and using analytics to improve operations. But, investments in the stock have been trashed. Traders have won over and over again. While growth will continue, and the balance sheet is solid, we have to keep an eye on the pace of customer growth and contract values. On the next drawdown to the $8 range, we would be buyers.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Utter Disaster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Utter Disaster\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-12 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4533226-palantir-utter-disaster><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryThere is no faith in Palantir right now.Headline results were mixed at best.Expenses are on the rise, but cash flow is positive and the balance sheet is pristine.The pace of growth is clearly ...</p>\n\n<a href=\"https://seekingalpha.com/article/4533226-palantir-utter-disaster\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4533226-palantir-utter-disaster","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190571853","content_text":"SummaryThere is no faith in Palantir right now.Headline results were mixed at best.Expenses are on the rise, but cash flow is positive and the balance sheet is pristine.The pace of growth is clearly slowing, and that is a major issue for an earnings-light company.So, Palantir Technologies Inc. (NYSE:PLTR) stock has been one of the best trading stocks you can ask for. It moves with extreme swings higher and lower, our traders have made a bundle, especially by selling premium (i.e., puts and calls). We have stood behind the technology as a gamechanger. This is truly an innovative and disruptive company that has massive reach to both the commercial and government sectors.The company is operating in the most important currency of our lifetimes: big data. And while the company innovates, and helps its clients understand data and make decisions, as an investment this has been complete trash, really an utter disaster. That may not be a technical finance term in the literature, but it is a term you hear often at hedge funds and trading floors. Frankly, while we believe in the ability of the company to deliver long-term, and we own some of it, it has been an utter disaster for longs that are not trading in and out. While we are up off the bottom, there are still so many retail \"bag-holders\" out there.Trading not investingThe only ones making money in this stock are trading in and out. You can make good money holding a core investment and selling calls, or even selling puts, due to the volatility. Those who scalp nickels and dimes are doing well. Those who are caught near the bottom are hit hard. But investing here requires extreme patience, and frankly, while we get the win on the trades over and over, we recognize that investors are getting slammed here.Pressure mountsUnfortunately, despite a market rally, this remains a trader's market right now, and we think that is the best way to handle Palantir for now. That said, we think you can hold a small core position for the long-term, but with all of the issues facing the company from dilution to a questionable management team, the economic picture has been poor for the company, making matters worse. Governments are spending less. Businesses are tightening up. While we think you can see business recognize the money saving potential of decision making algorithms, company capex on things like this tends to get cut first when businesses tighten their belt. This is a near-term issue, while things like dilution are longer-term. The thing is, we think you should trade this name. We hate to see investors lose money, and we know it can be painful, but it's been complete trash, in our humble opinion. Is all hope lost here?Companies like Palantir tend to be expensive before they finally sustain earningsCompanies like Palantir are indeed often extremely expensive in the early stages. Granted, this company has been around for a long time, but is newly public, barely two years old here public. You really cannot value them on an earnings basis because there are no or very little earnings often as they ramp up. Palantir, as we mentioned has that massive dilution problem, which means consistent positive EPS gets kicked further down the road. We think Palantir has a lot of potential, but this market is beyond unforgiving to those companies that do not make money or have sky high valuations. The last few weeks have seen a huge tech rally, and Palantir stock began to see a big bid up, until this week.Little faith in PalantirInvestors are now starting to see that Palantir may lose money or breakeven for years. Of course, the theory goes that companies like this will lose money as they spend to attract customers and build their moat. They invest heavily in their growth while seeing revenues increase dramatically. And as we know, Palantir is seeing revenues grow tremendously, but even that pace of growth is slowing, and that is a huge risk. If you believe in the tech (we do) you can add selectively to a well-rounded portfolio to improve cost basis, and put faith in management that it can deliver on growing the business profitably without diluting shareholders into oblivion, but it may take years to get a return. It is just easier to make 5,6,7, even 10% on this name by trading over and over. Investing requires patience and belief that things will improve. Right now, this is a tall order for this company and management. There is no, or very little faith.While operationally the company is growing sufficiently, management has some credibility issues. What one has to do is determine if what the company offers will solve enough headaches for customers that eventually the growing sales turn into sustained and growing profits. However, the most recent quarter was also \"trash,\" as we say.Headline earnings figures mixedIn the just-reported quarter, performance was pretty mixed on the top and bottom lines with revenue just a touch ahead of consensus estimates, and earnings missing horribly. Total revenue grew 25.9% year-over-year to $473.0 million, beating estimates by just over $1 million. However, its profitability was lower than expected by $0.04, and worse, guidance was far less than consensus. That crushed the stock's momentum that it had going for it. Now revenues are only growing in the 20% range, versus 30+. Ouch. Further, most expected the company to make a tiny profit this quarter, and instead it lost money. Ouch.Palantir's Government and Commercial sectors both showing growthAs you likely are aware, Palantir has two reporting segments: both the government and commercial segments. The commercial revenue stream continues to grow rapidly, while government results seem to be slowing. There is a ton of disagreement out there on whether the somewhat shaky economy will help or hurt, but we think it definitely slows both sectors, especially government.Deceleration of revenue growth is definitely a negative for a company like this that does not enjoy high earnings. The revenues did rise 26% from last year, and the company's customer count increased to 304, up from 169 a year ago, but sequentially customer growth seems to be slowing. Palantir added 27 net new customers in the second quarter, with 19 net new commercial customers. We think it is important to note that the commercial space is doing well. The commercial revenue is expanding rapidly, increasing 132% in 2021, and here in Q2, it rose 46% year-over-year. That said, each earnings report it seems the year-over-year growth is a little less. Not great.The government business growth has just stalled. Here government revenue expanded to $263 million in revenue in Q2, rising 9% quarter-over-quarter. One positive is that health care (both in government and also commercial) has become a substantial and rapidly growing business, generating approximately $153 million in revenue in the first half of 2022, up from $42 million in the first half of 2020. Decent growth.Margins show good newsFor as much as the company seemed to have whiffed, there has been pockets of good news. Palantir is seeing very positive momentum in its margins. Positive movement in margins is important in a software company as it really highlights strengths, or weaknesses, in the way it distributes its products. Palantir is delivering here. Adjusted gross margin, (these are the margins which excludes the horrible dilutive stock-based compensation expenses) was 81%. The adjusted income from operations, excluding stock-based compensation and related employer payroll taxes, was $108 million, representing adjusted operating margin of 23% ahead of management's prior guidance of 20%.Palantir expenses are on the rise but cash flow is positive.While margins were solid, adjusted expenses are on the rise. Expenses were $365 million, up 11% sequentially. With the revenue number and higher expenses however, despite margins, led to a loss in the quarter. As mentioned adjusted earnings per share was a loss of $0.01. Some of this was that there was a $0.05 impact driven primarily by losses on securities held.The company also generated $62 million in cash from operations, and the adjusted free cash flow was $61 million. That was the seventh consecutive quarter of positive free cash flow. Over the last year Palantir generated $314 million in adjusted free cash flow. The balance sheet is anything but trash. The company still has a solid $2.4 billion in cash and cash equivalents and absolutely no debt. Now that said, the company did decide a few weeks ago to expand its revolving credit facility by adding a $450 million new incremental delayed draw term loan facility. Long story short, the company has liquidity if needed. Overall, they have an additional liquidity source up to $950 million and it remains entirely undrawn.The reason we explain that is this company is in no danger of any sort of bankruptcies. The investment might be horrible as sustained positive EPS remains elusive, but the balance sheet is nice.Palantir stock valuationWhen we look at the valuation of Palantir stock, the bottom line is the stock is expensive to own. Sure, looking at traditional price-to-earnings is futile, but if you did you would see a stock at like 170X FWD EPS. Very pricey. Perhaps the more appropriate measure is the price-to-sales ratio, but not only is this still very high, the market has basically said it is no longer willing to pay for sky high multiples here in 2022. Keep that in mind. At 10.4X sales, the stock is relatively cheaper than it has ever been, but it is still not \"cheap\" by any stretch at all. We like the cash flow metrics, though the price to cash flow is still about 70X.Guidance was more than disappointingThe biggest concern right now is not valuation, or the Q2 earnings results. Nor is it the fact that the stock has been a trash investment. The biggest issue right now is also not the never ending dilution (which stinks). It is not the broader market risk either. The largest issue is a slowdown in performance, the slowing growth of revenues, and continued reduced guidance including here in Q3. The Q3 guidance was pretty weak. For Q3 2022, the company \"expects revenue of between $474 million to $475 million\" which was way below consensus of $505 million. For the year, we are looking at nearly 5% lower revenues than expected. Ouch. For the year management guided \"revenue of $1.9 billion\" vs. consensus of $1.98 billion. Adjusted income from operations should be $341 million to $343 million.So, what is our take?We would be selling calls here on the next pop. The volatility is high here and premiums are hefty. On the next big downturn, sell puts a month or two out and out of the money. If assigned, turn right around and sell calls. Trade around the position. Palantir's growth is slowly fading, though still strong. We also think profitability is elusive. Dilution could continue so long that positive EPS becomes out of reach without future buybacks. Stick to trading the name, or buy a few shares and come back in 10 years.Take homeWe love that the company operates with no debt and has nice positive free cash flow. The company offers amazing solutions for government and businesses by using big data and using analytics to improve operations. But, investments in the stock have been trashed. Traders have won over and over again. While growth will continue, and the balance sheet is solid, we have to keep an eye on the pace of customer growth and contract values. On the next drawdown to the $8 range, we would be buyers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":986,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9990129953,"gmtCreate":1660312121074,"gmtModify":1676533449064,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Long wait!!","listText":"<a href=\"https://ttm.financial/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Long wait!!","text":"$Zomedica Pharmaceuticals Corp.(ZOM)$Long wait!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9990129953","isVote":1,"tweetType":1,"viewCount":914,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9990120858,"gmtCreate":1660312073376,"gmtModify":1676533449048,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>💪💪","listText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>💪💪","text":"$T2 Biosystems(TTOO)$💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/9990120858","isVote":1,"tweetType":1,"viewCount":914,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9907150666,"gmtCreate":1660172020257,"gmtModify":1703478560328,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SUNW\">$Sunworks(SUNW)$</a>🤭","listText":"<a href=\"https://ttm.financial/S/SUNW\">$Sunworks(SUNW)$</a>🤭","text":"$Sunworks(SUNW)$🤭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9907150666","isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9061100608,"gmtCreate":1651580052994,"gmtModify":1676534929975,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061100608","repostId":"9061100143","repostType":1,"repost":{"id":9061100143,"gmtCreate":1651580033462,"gmtModify":1676534929958,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INUV\">$Inuvo(INUV)$</a>Long long wait!!&nbsp;","listText":"<a href=\"https://ttm.financial/S/INUV\">$Inuvo(INUV)$</a>Long long wait!!&nbsp;","text":"$Inuvo(INUV)$Long long wait!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061100143","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":566,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9061100143,"gmtCreate":1651580033462,"gmtModify":1676534929958,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INUV\">$Inuvo(INUV)$</a>Long long wait!!&nbsp;","listText":"<a href=\"https://ttm.financial/S/INUV\">$Inuvo(INUV)$</a>Long long wait!!&nbsp;","text":"$Inuvo(INUV)$Long long wait!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/9061100143","isVote":1,"tweetType":1,"viewCount":1064,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9086904002,"gmtCreate":1650409531725,"gmtModify":1676534715029,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/HMBL\">$HUMBL Inc.(HMBL)$</a>Sad 😞&nbsp;","listText":"<a href=\"https://ttm.financial/S/HMBL\">$HUMBL Inc.(HMBL)$</a>Sad 😞&nbsp;","text":"$HUMBL Inc.(HMBL)$Sad 😞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9086904002","isVote":1,"tweetType":1,"viewCount":791,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9016830543,"gmtCreate":1649164159337,"gmtModify":1676534461395,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Go go","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Go go","text":"$Tiger Brokers(TIGR)$Go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9016830543","isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9035982117,"gmtCreate":1647485600771,"gmtModify":1676534236488,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/LCLP\">$Life Clips, Inc.(LCLP)$</a>Sad","listText":"<a href=\"https://ttm.financial/S/LCLP\">$Life Clips, Inc.(LCLP)$</a>Sad","text":"$Life Clips, Inc.(LCLP)$Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035982117","isVote":1,"tweetType":1,"viewCount":848,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9033559073,"gmtCreate":1646319788599,"gmtModify":1676534116768,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BLQC\">$BlockQuarry Corp.(BLQC)$</a>[Cool]&nbsp;","listText":"<a href=\"https://ttm.financial/S/BLQC\">$BlockQuarry Corp.(BLQC)$</a>[Cool]&nbsp;","text":"$BlockQuarry Corp.(BLQC)$[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9033559073","isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001611174,"gmtCreate":1641244841496,"gmtModify":1676533586253,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AMLH\">$American Leisure Holdings, Inc.(AMLH)$</a>Nice","listText":"<a href=\"https://ttm.financial/S/AMLH\">$American Leisure Holdings, Inc.(AMLH)$</a>Nice","text":"$American Leisure Holdings, Inc.(AMLH)$Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9001611174","isVote":1,"tweetType":1,"viewCount":592,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863278662,"gmtCreate":1632403723256,"gmtModify":1676530773518,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Keep going!&nbsp;","listText":"Keep going!&nbsp;","text":"Keep going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/863278662","repostId":"1133566174","repostType":4,"repost":{"id":"1133566174","kind":"news","pubTimestamp":1632397453,"share":"https://ttm.financial/m/news/1133566174?lang=&edition=full_marsco","pubTime":"2021-09-23 19:44","market":"us","language":"en","title":"Despite Vaccine Uncertainty, Pfizer Is a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133566174","media":"InvestorPlace","summary":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a compan","content":"<blockquote>\n <b>Forget the booster shot controversy, PFE stock has better days ahead.</b>\n</blockquote>\n<p>What would happen if a company developed a massive new product and no <a href=\"https://laohu8.com/S/AONE.U\">one</a> cared? For&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s</b> investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.</p>\n<p>That finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?</p>\n<p><b>Vaccine Hits A Setback</b></p>\n<p>Pfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated <a href=\"https://laohu8.com/S/AFG\">American</a> adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.</p>\n<p>Despite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.</p>\n<p>The idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.</p>\n<p>This scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that&nbsp;<b>Moderna’s</b>(NASDAQ:<b><u>MRNA</u></b>) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.</p>\n<p>This is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.</p>\n<p><b>Baseline Valuation Is Not That Demanding</b></p>\n<p>Let’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.</p>\n<p>Based on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.</p>\n<p>Yes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.</p>\n<p><b>PFE Stock Verdict</b></p>\n<p>Right now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.</p>\n<p>For longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.</p>\n<p>The company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.</p>\n<p>If the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.</p>\n<p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Despite Vaccine Uncertainty, Pfizer Is a Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDespite Vaccine Uncertainty, Pfizer Is a Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the ...</p>\n\n<a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133566174","content_text":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.\nThat finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its Q2 earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?\nVaccine Hits A Setback\nPfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated American adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.\nDespite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.\nThe idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.\nThis scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that Moderna’s(NASDAQ:MRNA) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.\nThis is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.\nBaseline Valuation Is Not That Demanding\nLet’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.\nBased on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.\nYes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.\nPFE Stock Verdict\nRight now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.\nFor longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.\nThe company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.\nIf the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869458478,"gmtCreate":1632318581194,"gmtModify":1676530751068,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Keep going","listText":"Keep going","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869458478","repostId":"1191119345","repostType":4,"repost":{"id":"1191119345","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632317287,"share":"https://ttm.financial/m/news/1191119345?lang=&edition=full_marsco","pubTime":"2021-09-22 21:28","market":"us","language":"en","title":"U.S. stock market opens solidly higher Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1191119345","media":"Tiger Newspress","summary":"(Sept 22) U.S. stock market opens solidly higher Wednesday as investors await Fed decision and Everg","content":"<p>(Sept 22)&nbsp;U.S. stock market opens solidly higher Wednesday as investors await Fed decision and Evergrande worries ease.</p>\n<p>Airline shares, Carnival stocks are&nbsp;up in morning trading.<img src=\"https://static.tigerbbs.com/72dc2679e36dee4656279e312189a571\" tg-width=\"276\" tg-height=\"399\" referrerpolicy=\"no-referrer\"></p>\n<p>Dynavax&nbsp;surged&nbsp;over&nbsp;15%,&nbsp;as&nbsp;Dynavax partner Clover's COVID-19 vaccine shows 79% efficacy against Delta variant.</p>\n<p><img src=\"https://static.tigerbbs.com/b3072bfc6f3e8c31f419dd0e90990672\" tg-width=\"1189\" tg-height=\"586\" referrerpolicy=\"no-referrer\"></p>\n<p>China concepts stocks&nbsp;bounce&nbsp;in morning trading.<img src=\"https://static.tigerbbs.com/4245f5a3d5476db60da0daefd14cf40f\" tg-width=\"276\" tg-height=\"802\" width=\"100%\" height=\"auto\"></p>\n<p>The Fedwill conclude its two-day meetingon Wednesday and release a policy statement with economic and interest rate forecasts at 2 pm E.T. Chairman Jerome Powell will then hold a press conference after.</p>\n<p>The central bank has the difficult task of soothing markets during a tumultuous month, while at the same time preparing investors for the removal of some monetary stimulus. Powell has previously said a tapering of the Fed’s emergency $120 billion in bond buying could begin as soon as this year.</p>\n<p>“A dovish Fed (or even a Fed that meets expectations) could provide more of a relief rally today, but we continue to think the sheer number of unknowns remain a headwind that will keep markets volatile for the next few weeks, until there’s more clarity on the Fed, taxes, government funding and earnings,” Tom Essaye, founder of Sevens Report, said in a note.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock market opens solidly higher Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock market opens solidly higher Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-22 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 22)&nbsp;U.S. stock market opens solidly higher Wednesday as investors await Fed decision and Evergrande worries ease.</p>\n<p>Airline shares, Carnival stocks are&nbsp;up in morning trading.<img src=\"https://static.tigerbbs.com/72dc2679e36dee4656279e312189a571\" tg-width=\"276\" tg-height=\"399\" referrerpolicy=\"no-referrer\"></p>\n<p>Dynavax&nbsp;surged&nbsp;over&nbsp;15%,&nbsp;as&nbsp;Dynavax partner Clover's COVID-19 vaccine shows 79% efficacy against Delta variant.</p>\n<p><img src=\"https://static.tigerbbs.com/b3072bfc6f3e8c31f419dd0e90990672\" tg-width=\"1189\" tg-height=\"586\" referrerpolicy=\"no-referrer\"></p>\n<p>China concepts stocks&nbsp;bounce&nbsp;in morning trading.<img src=\"https://static.tigerbbs.com/4245f5a3d5476db60da0daefd14cf40f\" tg-width=\"276\" tg-height=\"802\" width=\"100%\" height=\"auto\"></p>\n<p>The Fedwill conclude its two-day meetingon Wednesday and release a policy statement with economic and interest rate forecasts at 2 pm E.T. Chairman Jerome Powell will then hold a press conference after.</p>\n<p>The central bank has the difficult task of soothing markets during a tumultuous month, while at the same time preparing investors for the removal of some monetary stimulus. Powell has previously said a tapering of the Fed’s emergency $120 billion in bond buying could begin as soon as this year.</p>\n<p>“A dovish Fed (or even a Fed that meets expectations) could provide more of a relief rally today, but we continue to think the sheer number of unknowns remain a headwind that will keep markets volatile for the next few weeks, until there’s more clarity on the Fed, taxes, government funding and earnings,” Tom Essaye, founder of Sevens Report, said in a note.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191119345","content_text":"(Sept 22) U.S. stock market opens solidly higher Wednesday as investors await Fed decision and Evergrande worries ease.\nAirline shares, Carnival stocks are up in morning trading.\nDynavax surged over 15%, as Dynavax partner Clover's COVID-19 vaccine shows 79% efficacy against Delta variant.\n\nChina concepts stocks bounce in morning trading.\nThe Fedwill conclude its two-day meetingon Wednesday and release a policy statement with economic and interest rate forecasts at 2 pm E.T. Chairman Jerome Powell will then hold a press conference after.\nThe central bank has the difficult task of soothing markets during a tumultuous month, while at the same time preparing investors for the removal of some monetary stimulus. Powell has previously said a tapering of the Fed’s emergency $120 billion in bond buying could begin as soon as this year.\n“A dovish Fed (or even a Fed that meets expectations) could provide more of a relief rally today, but we continue to think the sheer number of unknowns remain a headwind that will keep markets volatile for the next few weeks, until there’s more clarity on the Fed, taxes, government funding and earnings,” Tom Essaye, founder of Sevens Report, said in a note.","news_type":1},"isVote":1,"tweetType":1,"viewCount":244,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869423178,"gmtCreate":1632318025194,"gmtModify":1676530750744,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ISWH\">$ISW Holdings Inc.(ISWH)$</a>Amazing!&nbsp;","listText":"<a href=\"https://laohu8.com/S/ISWH\">$ISW Holdings Inc.(ISWH)$</a>Amazing!&nbsp;","text":"$ISW Holdings Inc.(ISWH)$Amazing!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869423178","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":312173066,"gmtCreate":1612077515855,"gmtModify":1704867156520,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Waiting for March!??","listText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Waiting for March!??","text":"$Zomedica Pharmaceuticals Corp.(ZOM)$Waiting for March!??","images":[{"img":"https://static.tigerbbs.com/8cb67f014ee00c9eaab8109a7a08c43d","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/312173066","isVote":1,"tweetType":1,"viewCount":910,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3560335834066942","authorId":"3560335834066942","name":"T20211216012","avatar":"https://static.tigerbbs.com/33d9d9696ede65b0e8970a9f0f615e2e","crmLevel":1,"crmLevelSwitch":0,"idStr":"3560335834066942","authorIdStr":"3560335834066942"},"content":"Is there anything good about March?","text":"Is there anything good about March?","html":"Is there anything good about March?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9990120858,"gmtCreate":1660312073376,"gmtModify":1676533449048,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>💪💪","listText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>💪💪","text":"$T2 Biosystems(TTOO)$💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/9990120858","isVote":1,"tweetType":1,"viewCount":914,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":383651329,"gmtCreate":1612876128361,"gmtModify":1704875267530,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Yeah!! Going to chiong tonight?&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Yeah!! Going to chiong tonight?&nbsp;","text":"$Bionano Genomics(BNGO)$Yeah!! Going to chiong tonight?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/383651329","isVote":1,"tweetType":1,"viewCount":1026,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344258924,"gmtCreate":1618411649268,"gmtModify":1704710480589,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>Jia you!!! Please up up ?&nbsp;","listText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>Jia you!!! Please up up ?&nbsp;","text":"$HUMBL Inc.(HMBL)$Jia you!!! Please up up ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/344258924","isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572494121485245","authorId":"3572494121485245","name":"gt96","avatar":"https://static.tigerbbs.com/f5c621467d68fd369e2a989ac58beb01","crmLevel":2,"crmLevelSwitch":1,"idStr":"3572494121485245","authorIdStr":"3572494121485245"},"content":"Yes. this one cfm up. See back 1year then thank yourself!!","text":"Yes. this one cfm up. See back 1year then thank yourself!!","html":"Yes. this one cfm up. See back 1year then thank yourself!!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350617447,"gmtCreate":1616200919789,"gmtModify":1704792089681,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/350617447","repostId":"2120117582","repostType":2,"isVote":1,"tweetType":1,"viewCount":510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931509291,"gmtCreate":1662474744013,"gmtModify":1676537068555,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>Really sad","listText":"<a href=\"https://ttm.financial/S/TTOO\">$T2 Biosystems(TTOO)$</a>Really sad","text":"$T2 Biosystems(TTOO)$Really sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/9931509291","isVote":1,"tweetType":1,"viewCount":1519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119554788,"gmtCreate":1622556279544,"gmtModify":1704186270805,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Top","listText":"Top","text":"Top","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/119554788","repostId":"2138889344","repostType":4,"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386505383,"gmtCreate":1613194414242,"gmtModify":1704879380271,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Nice!","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Nice!","text":"$Bionano Genomics(BNGO)$Nice!","images":[{"img":"https://static.tigerbbs.com/874ef4cf34ccef4641aa2378ebf22b83","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/386505383","isVote":1,"tweetType":1,"viewCount":451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":318560721,"gmtCreate":1611873370863,"gmtModify":1704865075145,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Long wait.. still waiting.. :(&nbsp;","listText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>Long wait.. still waiting.. :(&nbsp;","text":"$Zomedica Pharmaceuticals Corp.(ZOM)$Long wait.. still waiting.. :(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/318560721","isVote":1,"tweetType":1,"viewCount":1179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9061100143,"gmtCreate":1651580033462,"gmtModify":1676534929958,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INUV\">$Inuvo(INUV)$</a>Long long wait!!&nbsp;","listText":"<a href=\"https://ttm.financial/S/INUV\">$Inuvo(INUV)$</a>Long long wait!!&nbsp;","text":"$Inuvo(INUV)$Long long wait!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/9061100143","isVote":1,"tweetType":1,"viewCount":1064,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9086904002,"gmtCreate":1650409531725,"gmtModify":1676534715029,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/HMBL\">$HUMBL Inc.(HMBL)$</a>Sad 😞&nbsp;","listText":"<a href=\"https://ttm.financial/S/HMBL\">$HUMBL Inc.(HMBL)$</a>Sad 😞&nbsp;","text":"$HUMBL Inc.(HMBL)$Sad 😞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9086904002","isVote":1,"tweetType":1,"viewCount":791,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362816428,"gmtCreate":1614611953164,"gmtModify":1704773105559,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INUV\">$Inuvo(INUV)$</a>Seeing light!!","listText":"<a href=\"https://laohu8.com/S/INUV\">$Inuvo(INUV)$</a>Seeing light!!","text":"$Inuvo(INUV)$Seeing light!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/362816428","isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382083354,"gmtCreate":1613303902578,"gmtModify":1704879828317,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/382083354","repostId":"2110904027","repostType":4,"isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119030030,"gmtCreate":1622507835520,"gmtModify":1704185229157,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Positive news&nbsp;","listText":"Positive news&nbsp;","text":"Positive news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119030030","repostId":"1163643126","repostType":4,"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355980482,"gmtCreate":1617024058546,"gmtModify":1704800960536,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/355980482","repostId":"2123535672","repostType":4,"isVote":1,"tweetType":1,"viewCount":304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":315187558,"gmtCreate":1612222516174,"gmtModify":1704868377755,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>??","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>??","text":"$Sundial Growers Inc.(SNDL)$??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/315187558","isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9033559073,"gmtCreate":1646319788599,"gmtModify":1676534116768,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BLQC\">$BlockQuarry Corp.(BLQC)$</a>[Cool]&nbsp;","listText":"<a href=\"https://ttm.financial/S/BLQC\">$BlockQuarry Corp.(BLQC)$</a>[Cool]&nbsp;","text":"$BlockQuarry Corp.(BLQC)$[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9033559073","isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863278662,"gmtCreate":1632403723256,"gmtModify":1676530773518,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Keep going!&nbsp;","listText":"Keep going!&nbsp;","text":"Keep going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/863278662","repostId":"1133566174","repostType":4,"repost":{"id":"1133566174","kind":"news","pubTimestamp":1632397453,"share":"https://ttm.financial/m/news/1133566174?lang=&edition=full_marsco","pubTime":"2021-09-23 19:44","market":"us","language":"en","title":"Despite Vaccine Uncertainty, Pfizer Is a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133566174","media":"InvestorPlace","summary":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a compan","content":"<blockquote>\n <b>Forget the booster shot controversy, PFE stock has better days ahead.</b>\n</blockquote>\n<p>What would happen if a company developed a massive new product and no <a href=\"https://laohu8.com/S/AONE.U\">one</a> cared? For&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>’s</b> investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.</p>\n<p>That finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its <a href=\"https://laohu8.com/S/QTWO\">Q2</a> earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?</p>\n<p><b>Vaccine Hits A Setback</b></p>\n<p>Pfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated <a href=\"https://laohu8.com/S/AFG\">American</a> adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.</p>\n<p>Despite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.</p>\n<p>The idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.</p>\n<p>This scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that&nbsp;<b>Moderna’s</b>(NASDAQ:<b><u>MRNA</u></b>) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.</p>\n<p>This is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.</p>\n<p><b>Baseline Valuation Is Not That Demanding</b></p>\n<p>Let’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.</p>\n<p>Based on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.</p>\n<p>Yes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.</p>\n<p><b>PFE Stock Verdict</b></p>\n<p>Right now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.</p>\n<p>For longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.</p>\n<p>The company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.</p>\n<p>If the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.</p>\n<p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Despite Vaccine Uncertainty, Pfizer Is a Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDespite Vaccine Uncertainty, Pfizer Is a Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the ...</p>\n\n<a href=\"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/09/despite-vaccine-uncertainty-pfizer-is-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133566174","content_text":"Forget the booster shot controversy, PFE stock has better days ahead.\n\nWhat would happen if a company developed a massive new product and no one cared? For Pfizer’s investors, that has been the question for the past year. Despite coming up with a blockbuster vaccine for the novel coronavirus, PFE stock did basically nothing for an extended period.\nThat finally changed this summer, when Pfizer belatedly rallied to new all-time highs. Now though, the gains are fading almost as quickly as they happened. In its Q2 earnings release, Pfizer reported 93% year-over-year revenue growth. Yet shares are up less than 20% over the past 12 months. Why have investors not given Pfizer credit for its performance, and will that change in the future?\nVaccine Hits A Setback\nPfizer has enjoyed incredible revenue growth over the past year due to its Covid-19 vaccine. The majority of vaccinated American adults have taken the Pfizer vaccine, and it’s had strong sales overseas as well.\nDespite that, however, PFE stock didn’t move too much. At least, not until July of this year. At that time, PFE stock finally took off. The reason why is that investors started to price in the expectation that people would need to take vaccine booster shots to maintain efficacy.\nThe idea of a third, and potentially even fourth or more dose of vaccines would have created a far more enduring revenue boost for Pfizer. Up until recently, investors had shied away from Pfizer despite its massive top-line growth because they anticipated that the Covid business would quickly recede. With booster shots, however, the vaccine would have taken on another level of importance to the company.\nThis scenario is now under increasing doubt, however. A Food and Drug Administration (FDA) advisory panel recentlyrecommended againstadvising booster shots of the Pfizer vaccine. A large majority of the panelists voted that the data on hand was insufficient to warrant booster shots. That comes amid reports that Moderna’s(NASDAQ:MRNA) vaccine remains effective in a higher percentage of people than Pfizer’s after 120 days.\nThis is hardly the final word on booster shots or the efficacy of Moderna versus Pfizer. Pfizer’s investors shouldn’t discount the possibility that the FDA later comes around on additional rounds of the vaccine. For now, however, the prospects are looking more uncertain.\nBaseline Valuation Is Not That Demanding\nLet’s go back in time to 2019 and pretend that we’ve never heard of the pandemic. What does an investment in Pfizer look like in this hypothetical scenario? For full-year 2018, Pfizer generated $1.87 of EPS. In 2019, this leapt to $2.87.\nBased on today’s stock price just below $44, PFE stock is selling at 23x 2018 earnings or 15x 2019 earnings. With no benefit from the current Covid-19 vaccine whatsoever, Pfizer stock would still be going for a reasonable multiple.\nYes, you can argue that pharmaceutical companies should trade for lower P/E multiples than many other industries given the high cost of drug development and quick patent expiries. Still, with earnings as strong as they were in 2018-19, it’s not hard to get behind the stock at $44 even if you give the company zero credit for the Covid-19 vaccine. Forget about booster shots for a minute, traders are pricing Pfizer like there will be little more revenue from the vaccine whatsoever.\nPFE Stock Verdict\nRight now, Pfizer stock is inextricably linked to its vaccine’s outlook. When there is positive news on that front, PFE stock surges. When there is a setback, PFE stock sells off hard. That’s a totally understandable market reaction. Many traders are trained to react quickly to the latest headline.\nFor longer-term investors, however, Pfizer is an opportunity regardless of the trajectory of the vaccine. Even if boosters ultimately aren’t a big thing, Pfizer can still make investors money from this entry point.\nThe company is a tremendous diversified pharmaceutical giant. It was in good shape long before the pandemic, and it has dozens of promising drugs in its pipeline to power it for the next decade and beyond. The company is reaping a windfall right now, but it’s not like that’s its only iron in the fire.\nIf the Covid-19 business continues longer than forecast, that’s all upside to the stock price. However, from this starting point, there’s sufficient margin of safety to support a purchase in most possible outcomes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119030402,"gmtCreate":1622507855106,"gmtModify":1704185227845,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Good news&nbsp;","listText":"Good news&nbsp;","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/119030402","repostId":"2140545174","repostType":4,"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375619766,"gmtCreate":1619331434855,"gmtModify":1704722574766,"author":{"id":"3572316149124317","authorId":"3572316149124317","name":"川姐","avatar":"https://static.tigerbbs.com/28a87e149cd4b977f188b8ae3cb01bd8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572316149124317","authorIdStr":"3572316149124317"},"themes":[],"htmlText":"Cool&nbsp;","listText":"Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375619766","repostId":"2129735285","repostType":4,"isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}